Dec 5, 2024 · The FDA’s decision to exclude NMN from being defined as a supplement has had an enormously adverse effect on the NMN market, valued at an estimated $280.2 million in the US in 2022. Along those lines, Amazon, the world’s largest sales platform, prohibited retailers from selling NMN beginning in March 2023.

May 24, 2024 · According to the Food and Drug Administration (FDA), NMN cannot lawfully be marketed as a dietary supplement in the U.S.; however, plenty of manufacturers sell it, boasting its purported...

WASHINGTON – A federal court today issued a significant ruling in a lawsuit brought by the Natural Products Association (NPA) against the Food and Drug Administration (FDA) requesting that the agency cease its unlawful retroactive application of the Food, Drug, and Cosmetic Act against Nicotinamide Mononucleotide (NMN).

Nov 30, 2022 · The FDA has issued a statement saying that NMN may not be sold as a supplement, citing its status as being under investigation as a drug. This development is a reversal of the FDA’s previous decision to allow its sale as a new dietary supplement (NDI).

Sep 27, 2024 · November 2022: The FDA begins investigating NMN's status as a new dietary ingredient (NDI) due to its growing use and the potential for drug classification. Early 2023: NMN is removed from the market as the FDA considers it for drug classification, largely due to its promising anti-aging research.

Nov 14, 2022 · The FDA recently published responses to several new dietary ingredient notifications (NDIN) submitted for nicotinamide mononucleotide (most notably the November 8, 2022 response to Inner Mongolia Kingdomway Pharmaceutical Ltd. “Kingdomway”).

Aug 28, 2024 · An investigational new drug application (IND) filed with FDA — and the clinical trials involving Metro’s MIB-626 that have been instituted and made public — have shaped FDA’s conclusion that NMN cannot be marketed in dietary supplement products.

Nov 14, 2022 · Regulator’s decision based on NMN’s investigation for use as a pharmaceutical drug – sparks immediate response from the Council for Responsible Nutrition. The United States Food & Drug Administration has said popular longevity supplement ingredient beta-nicotinamide mononucleotide (NMN) cannot be sold as a dietary supplement in the US.

Aug 21, 2023 · In November of 2022, the Federal Drug Administration (FDA) reversed its decision to allow nicotinamide mononucleotide (NMN) to be marketed as a dietary supplement because it is being investigated as a new drug.

The pharma company agreed with FDA that NMN is properly barred from being marketed as a dietary supplement under the so-called drug exclusion clause of the Federal Food, Drug & Cosmetic Act (FDCA).